Faster approvals, smarter oversight
Regulatory AI is no longer optional — it’s the competitive edge life sciences companies can’t afford to ignore. As global regulatory demands grow more complex and submission delays jeopardize time to market, pharmaceutical organizations face a critical inflection point. Companies that embrace AI-driven submissions, validation, and compliance will move faster, avoid costly errors, and secure market access ahead of their competitors.
Natural language processing (NLP) and large language models (LLMs) are subsets of AI with clear value in pharmaceutical regulation. NLP enables rapid analysis of regulatory documents, adverse event reports, and patient narratives. LLMs, such as GPT-based models, extend this by generating summaries, supporting decision-making, and drafting submissions at scale. Together, they enhance communication, ensure consistency, and accelerate the synthesis of vast amounts of scientific literature.
Regulatory oversight is rigorous and resource-intensive, spanning drug approvals, pharmacovigilance, and compliance monitoring. AI is emerging not just as a tool but as a new operating model, one that streamlines data analysis, improves predictive accuracy, and enables faster, more reliable decisions that ultimately serve public health.
Despite its potential, many leaders struggle with how to deploy AI without compromising compliance or trust. Arthur D. Little (ADL) proposes two strategic hypotheses:
These hypotheses guide this Viewpoint’s exploration of governance, roadmaps, and case studies. The message is clear: the opportunity is real, the tools are ready, and early movers will define the future of regulatory operations.
AI systems can process data at a scale far beyond human capacity, enabling the detection of safety risks, the identification of counterfeit drugs, and the improvement of trial design. However, there are transparency, reproducibility, and accountability challenges related to AI integration. Regulatory authorities must establish clear standards for validation, reliability, and bias mitigation while ensuring privacy and ethical use.
Successful adoption will require collaboration among regulators, industry, and AI developers. Shared learning, standardized practices, and continuous dialogue will underpin effective governance. Done thoughtfully, AI will strengthen oversight and deliver safer, more effective treatments for patients worldwide.
Across the drug development lifecycle, there are numerous inflection points where AI can be applied to enhance regulatory performance. Beyond long-term transformation, AI offers immediate, tactical benefits like streamlining the day-to-day operations of regulatory teams.
Regulatory compliance in life sciences is governed by a complex and constantly evolving set of requirements from agencies such as the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), Japan’s Pharmaceuticals and Medical Devices Agency (PMDA), and the National Medical Products Administration (NMPA) in China. Traditional submission processes present persistent challenges:
An organization’s appetite for AI innovation will vary depending on its digital maturity and strategic objectives. AI can be deployed in modular, low-effort ways that deliver quick wins or through bold, end-to-end transformations that redefine regulatory operations. Recognizing these challenges, regulatory authorities worldwide are beginning to address AI integration through formal guidance and frameworks (see Figure 1):
All of the above countries, along with Singapore and Australia, are providing AI guidance for software as a medical device.
The stage is set, but the regulatory environment remains intricate. Organizations that proactively adapt will be better positioned to navigate complexity, accelerate approvals, and lead the industry.
Although the tools vary, AI is being integrated into every aspect of the drug development lifecycle (see Figure 2). Below, we examine its use in the five strategic areas of automating submissions, monitoring compliance, staying ahead of regulations, labeling, and extracting actionable real-world evidence and wearable device data.
AI can significantly streamline regulatory submission workflows, beginning with electronic common technical document (eCTD) summary sections. Tools that automate the assembly of CTD and eCTD documents improve accuracy and efficiency, helping regulatory teams generate draft dossiers much faster. What traditionally takes eight to nine months can be shortened by several weeks (up to ~60% time savings from draft generation to final submission).
In parallel, NLP enhances standardization and compliance by ensuring consistent terminology, correcting regulatory phrasing, and providing automatic translation when needed. These capabilities reduce error rates with industry benchmarks suggesting resubmission cost avoidance in the range of tens to hundreds of thousands of US dollars per submission. Overall, LLM-based AI platforms have shown reduced initial drafting time by 97%.
Lastly, AI-driven validation tools offer real-time checks against evolving regional regulatory requirements. By identifying issues early, these systems improve submission readiness and reduce review cycles. For organizations regularly engaging with agencies like the FDA or EMA, these improvements have been associated with an ROI of 100%-200% within one to two years, according to IBM.
AI is transforming the way regulatory teams monitor and respond to global changes. By continuously scanning regulatory publications from agencies like the FDA, EMA, and ICH (International Council for Harmonisation), AI systems can rapidly flag relevant updates within seconds rather than hours. This automation reduces the manual burden on teams, frees up valuable resources, and ensures proactive, real-time compliance. Demonstrating such responsiveness is increasingly valued by regulators and can be a differentiator in inspections or audits.
In the realm of pharmacovigilance, AI accelerates adverse event (AE) reporting. Using NLP and machine learning (ML) to analyze real-world data and literature, AI-powered literature reviews can be completed in 30 seconds per article instead of 50 hours, freeing up to 89.5% of pharmacovigilance professionals’ time. This strengthens patient safety and helps organizations avoid costly penalties, trial delays, and even product recalls, often costing hundreds of thousands to millions of dollars. By integrating AI into AE surveillance, regulatory teams can deliver faster, smarter, and more compliant safety reporting.
AI is a powerful tool for extracting insights from historical regulatory data. By identifying trends, recurring pitfalls, and common bottlenecks, AI enables regulatory teams to focus on high-impact areas and make smarter, more data-driven decisions. Complex datasets that would traditionally take weeks to analyze can be processed 50%-80% faster, accelerating strategic planning and submission preparation. These insights reduce risks while strengthening credibility with regulators through more targeted and better-prepared submissions.
In parallel, AI-driven regulatory intelligence systems help organizations stay ahead of evolving global requirements. By continuously tracking and interpreting changes in regulatory landscapes, AI reduces the risk of noncompliance while optimizing submission timing and market-entry strategies. This strategic alignment boosts competitiveness and can be especially valuable in fast-moving or crowded therapeutic areas.
AI-powered translation tools, particularly those using LLMs trained on existing regulatory label data, are transforming the label localization process.
These tools can semi-automate translations of labels following updates to the Company Core Data Sheet (CCDS) or changes in local regulatory requirements, offering a fast and scalable alternative to traditional manual workflows.
By reducing the need for multiple review cycles, ADL analysis shows that AI can compress translation timelines from roughly seven days to one, with up to 95% initial accuracy. Although final review and minor adjustments by regulatory professionals are still needed, the reduction in overall effort lets teams focus on quality assurance and strategic localization planning rather than repetitive linguistic tasks.
AI plays a critical role in extracting actionable real-world evidence (RWE) to support regulatory decision-making. By automating the analysis of large, complex datasets, AI accelerates insight generation and ensures compliance with evolving safety and monitoring standards. These systems enable early detection of AEs and support continuous safety surveillance, reducing regulatory risk and improving outcomes. Organizations leveraging AI for RWE can reduce reporting timelines by 50%, avoiding delays and preventing costly penalties or product recalls (which often exceed millions of US dollars per incident).
AI is also being applied to wearable device data, which presents both opportunities and challenges for regulatory submissions. Advanced algorithms validate data integrity, generate real-time insights into patient safety and product performance, and streamline the reporting process. This reduces manual workload while ensuring wearable data can be seamlessly integrated into compliant submissions. AE event detection via AI tools in this context mirrors efficiency gains seen in literature-based monitoring, saving weeks or months in safety assessment and supporting faster, more informed regulatory responses.
AI has shifted from a peripheral innovation to a core driver of regulatory excellence. In today’s compliance environment — where accuracy, transparency, and accountability are mandatory — AI enables a move from manual oversight to intelligent, proactive governance that is secure, resilient, and strategically aligned.
AI’s greatest value lies in improving data quality. ML models can scan vast datasets to detect anomalies, inconsistencies, and risks before they affect submissions or patient safety. This predictive capability shifts governance from reactive correction to real-time assurance, ensuring regulatory decisions rest on validated information.
AI enhances accountability by mapping data lineage, logging changes, and generating audit-ready documentation. These capabilities are critical under growing regulatory scrutiny, where explainability and traceability are required by both regulators and stakeholders.
AI enforces governance by securing sensitive data through privacy by design. Advanced algorithms detect breaches, respond in real time, and support compliance with global and local standards (e.g., GDPR and CCPA [California Consumer Privacy Act]) through classification and anonymization. The result is greater trust, reduced risk, and improved resilience.
Despite its promise, AI-driven governance faces major obstacles:
As regulatory expectations evolve, governance frameworks must be agile, explainable, adaptable, and capable of meeting shifting guidelines without sacrificing control or transparency. To overcome these barriers, organizations must act decisively by:
This is more than a technology upgrade. It is an opportunity to redefine governance as a strategic enabler, supporting not only regulatory compliance but also organizational intelligence and agility. By addressing both structural and cultural challenges directly, organizations can unlock the full potential of AI and build regulatory functions that are compliant, adaptive, and future-ready.
Case study: Converse with your data
This case study describes how leading organizations successfully applied ADL-built AIsolutions to specific regulatory challenges toachieve positive ROI.
Deterministic & probabilistic AI
Deterministic AI systems are rule-based, producing outcomes that are predictable, repeatable, and explainable. They are grounded in explicit logic, mathematical rules, or engineered knowledge bases, making them highly reliable and suitable for regulated environments such as healthcare and pharmaceuticals. Their main limitation is inflexibility: they struggle in dynamic contexts where rules may be incomplete or outdated. Probabilistic AI leverages statistics and ML to capture patterns in data and adapt to variability. Rather than fixed outputs, it assigns likelihoods and continuously refines predictions. This makes it powerful in handling uncertainty and incomplete information, but it introduces challenges around explainability, bias, and regulatory acceptance. The real power comes from combining the approaches. Deterministic systems provide the necessary guardrails, safety checks, and transparency; probabilistic models add adaptability and predictive strength. In practice, deterministic logic ensures compliance and interpretability while probabilistic reasoning optimizes decision-making in uncertain environments.
Challenge
The FDA initially released 202 Complete Response Letters (CRLs) with potentially valuable knowledge and insights that organizations can prepare and learn from, with additional letters released ongoing. However, these documents are lengthy, unstructured, and difficult to systematically analyze, making it challenging for regulatory teams to extract consistent, actionable intelligence at scale.
Solution
ADL built a system that combines structured organization with advanced AI search to unlock insights from FDA CRLs. Each letter was broken into meaningful sections, enriched with metadata (e.g., therapeutic area, issue type), and stored in a vector database (Pinecone). This structure allows an LLM (in this case, OpenAI 4.1) to efficiently retrieve relevant passages and provide clear, targeted answers to user queries. Regulatory teams can ask natural questions of hundreds ofCRLs and instantly surface the most relevant examples, trends, and findings, turning a large volume of complex documents into actionable intelligence.
Result
This solution led to the ability to have a conversation with the data. Instead of combing through hundreds of dense FDA CRLs, users can ask questions such as: “What are the most common issues flagged in oncology submissions?” or “How often does manufacturing data delay approvals?” The system responds with precise excerpts, patterns, and summaries drawn directly from the letters. This conversational interface transforms static regulatory documents into an interactive knowledge base, helping teams explore trends, uncover lessons learned, and effectively prepare regulatory submissions.
Realizing the promise of AI requires more than belief in its potential; it requires disciplined execution. In regulatory operations, success comes not from theory but from translating vision into structured, measurable progress. The path forward is clear: combine the strategic foresight of a roadmap with the human-centered adoption of new tools:
cloud technology axon
Since its public launch in 2025, the platform has served more than 200...
